Creatine: a nitrogen compound of muscle energy metabolism
Creatine is among the most thoroughly studied substances in sports nutrition, with several hundred controlled trials published since the early 1990s. It is also a normal constituent of the human body and of a meat-containing diet. This article describes the chemistry, the biosynthesis, the content in food, the manufacturing routes, the available forms and the state of research.
Chemistry and discovery
Creatine, systematically 2-(methylguanidino)acetic acid, is a small nitrogen-containing compound with the formula C4H9N3O2. It carries a guanidino group, which makes it strongly basic, and a carboxyl group, so that it is present in the body as a zwitterion. The French chemist Michel Eugene Chevreul isolated it in 1832 from meat extract and named it after the Greek word for flesh. In 1927, Fiske and Subbarow described creatine phosphate in muscle, which established the biochemical context in which the compound is understood today.
In aqueous solution, creatine slowly cyclises to creatinine, a reaction that is faster at low pH and at higher temperature. This degradation is the reason products are sold as a dry powder and are mixed shortly before intake.
Biosynthesis and the body pool
The human body synthesises creatine in two enzymatic steps. The enzyme AGAT transfers an amidino group from arginine to glycine, producing guanidinoacetate, mainly in the kidney and pancreas. The enzyme GAMT then methylates this intermediate using S-adenosylmethionine, primarily in the liver. Creatine released into the blood is taken up by tissues through the transporter SLC6A8, which depends on sodium and chloride.
About 95 percent of the body pool is located in skeletal muscle, with smaller amounts in heart, brain and testes. Total muscle content is usually given as roughly 120 to 140 millimoles per kilogram of dry muscle, of which about two thirds is present as phosphocreatine. Each day, between one and two percent of the pool is converted non-enzymatically to creatinine and excreted by the kidneys; this loss is replaced by biosynthesis and by food.
Occurrence in food
Creatine occurs almost exclusively in animal tissue. Raw beef and pork contain roughly 4 to 5 g per kilogram, herring is often cited with higher values, and salmon and cod lie in a similar range to meat. Cooking converts part of it to creatinine. Measurements of muscle content in people on vegetarian and vegan diets show lower average values than in omnivores, which is consistent with the absence of dietary intake.
Biochemical role
The enzyme creatine kinase catalyses the reversible transfer of a phosphate group between ATP and creatine. The resulting phosphocreatine acts as a rapidly accessible phosphate reservoir. During the first seconds of a maximal effort, when the demand for ATP exceeds what glycolysis and oxidative phosphorylation can deliver, phosphocreatine regenerates ATP from ADP. Isoforms of creatine kinase in the mitochondria and at the myofibril form what the literature calls the phosphocreatine shuttle, a transport system for high-energy phosphate within the cell.
Manufacture and purity
Creatine monohydrate is produced chemically, usually from sodium sarcosinate and cyanamide, which react in aqueous solution and crystallise as the monohydrate. The relevant purity parameters are the residual content of creatinine, of dicyandiamide and of dihydrotriazine, all of them by-products of the synthesis, together with limits for heavy metals. Some manufacturers publish batch analyses; the trade name Creapure designates a German production site that does so.
Forms on the market
- Creatine monohydrate: the form used in the great majority of published trials, and the cheapest. Micronised variants have a smaller particle size and disperse more easily in water.
- Creatine hydrochloride: more soluble in water. Comparative studies examining muscle creatine content or performance parameters against monohydrate are few.
- Creatine ethyl ester: a pharmacokinetic study reported that the ester is largely hydrolysed to creatinine in the stomach and raised muscle creatine less than monohydrate.
- Buffered creatine: marketed with the argument of greater stability at gastric pH. A randomised comparison with monohydrate reported no difference in muscle creatine content or in the performance parameters measured.
- Creatine citrate, malate and nitrate: salts with differing solubility; the creatine share per gram of product is lower than in the monohydrate, and comparative data are limited.
Research findings
- Muscle content: studies using muscle biopsy and magnetic resonance spectroscopy report an increase of roughly 20 percent in total muscle creatine after a loading regimen, with large differences between individuals; participants starting from low values show the largest increase, while some show almost none.
- Resistance training: meta-analyses of randomised trials in which creatine intake accompanied a training programme report differences in lean body mass and in maximal strength compared with training plus placebo. Part of the measured mass difference is attributed to intracellular water.
- Repeated high-intensity efforts: trials using sprint and interval protocols report differences in work performed in later repetitions. Trials of continuous endurance performance generally report no difference.
- Body mass: an increase of one to two kilograms within the first week of a loading regimen is consistently reported and is attributed to water retained in muscle cells.
- Cognition: small randomised trials have examined memory and reaction tasks during creatine intake, among them studies in vegetarians and under sleep deprivation. A 2023 meta-analysis of such trials reported differences on some memory measures, with the authors noting small samples and heterogeneous test batteries.
- Neurological conditions: large trials have been conducted in neurodegenerative disease. The CREST-E trial in Huntington disease, with 553 participants receiving up to 40 g daily, was stopped in 2014 for futility, as was a large trial in Parkinson disease with 1741 participants reported in 2015. Trials in amyotrophic lateral sclerosis likewise reported no difference from placebo.
- Older adults: trials combining creatine intake with resistance training in participants over 60 report differences in measured strength and lean mass against training alone; the trials are short and the participant numbers moderate.
Doses used in trials follow two patterns: a loading phase of about 20 g per day divided into four portions over five to seven days, followed by 3 to 5 g per day, or 3 to 5 g per day from the outset, which studies show fills the muscle pool more slowly and reaches a similar level after about four weeks. These are study doses.
Safety data and precautions
- Long-term studies in healthy adults, some running for several years, have measured markers of kidney and liver function and reported no changes attributable to intake. This applies to healthy adults at the doses studied.
- Creatine intake raises serum creatinine, the laboratory value used to estimate kidney function, without indicating kidney damage. Laboratory results can therefore be misread; the physician ordering the test should be told about the intake.
- People with existing kidney disease, and people taking medicines that affect the kidney, should seek medical advice before use.
- Gastrointestinal complaints are reported mainly with large single doses; dividing the dose is the usual response described in the literature.
- Data on use in pregnancy and breastfeeding are insufficient.
- Data in children and adolescents are more limited than in adults; use in minors is a matter for a physician.
- The frequently repeated statements that creatine is a steroid, that it damages the kidneys of healthy people or that it causes dehydration are not matched by the published data; controlled trials have examined hydration and thermoregulation without finding the effects claimed.
Regulatory status
Creatine is marketed in the EU as a food supplement. Under Regulation (EU) No 432/2012, an authorised claim exists linking creatine to physical performance in successive bursts of short-term, high-intensity exercise, with a stated condition of 3 g of creatine per day; a further authorised claim concerns creatine in combination with resistance training in adults over 55. The exact wording and conditions are laid down in the EU register of authorised claims.